These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15537567)

  • 1. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy.
    Kuti JL; Moss KM; Nicolau DP; Knauft RF
    Pharmacotherapy; 2004 Nov; 24(11):1641-5. PubMed ID: 15537567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful meropenem desensitization in a patient with cystic fibrosis.
    Wilson DL; Owens RC; Zuckerman JB
    Ann Pharmacother; 2003 Oct; 37(10):1424-8. PubMed ID: 14519038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.
    Nicasio AM; Quintiliani R; DeRyke CA; Kuti JL; Nicolau DP
    Ann Pharmacother; 2007 Jun; 41(6):1077-81. PubMed ID: 17472997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy.
    Weidmann A; Webb AK; Dodd ME; Jones AM
    J Cyst Fibros; 2008 Sep; 7(5):409-11. PubMed ID: 18356119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia.
    Aaron SD; Ferris W; Henry DA; Speert DP; Macdonald NE
    Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1206-12. PubMed ID: 10764313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burkholderia cepacia septicemia in a pediatric oncology patient: a pharmacotherapy challenge.
    Durham SH; Lee AE; Assanasen C
    Ann Pharmacother; 2012 Jun; 46(6):e16. PubMed ID: 22570430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of pulmonary infection in cystic fibrosis.
    Webb AK
    Scand J Infect Dis Suppl; 1995; 96():24-7. PubMed ID: 7652499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
    Zhou J; Chen Y; Tabibi S; Alba L; Garber E; Saiman L
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1085-8. PubMed ID: 17158942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
    Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
    Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy.
    Cantón-Bulnes ML; Hurtado Martínez Á; López-Cerero L; Arenzana Seisdedos Á; Merino-Bohorquez V; Garnacho-Montero J
    Transpl Infect Dis; 2019 Apr; 21(2):e13034. PubMed ID: 30548546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids.
    Gilchrist FJ; Webb AK; Bright-Thomas RJ; Jones AM
    J Cyst Fibros; 2012 Sep; 11(5):458-60. PubMed ID: 22551926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temocillin in the treatment of Burkholderia cepacia infection in cystic fibrosis.
    Lekkas A; Gyi KM; Hodson ME
    J Cyst Fibros; 2006 May; 5(2):121-4. PubMed ID: 16650744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.
    Jaruratanasirikul S; Sriwiriyajan S; Punyo J
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1337-9. PubMed ID: 15793108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical necrotizing fasciitis: a novel clinical presentation of Burkholderia cepacia infection.
    Marioni G; Rinaldi R; Ottaviano G; Marchese-Ragona R; Savastano M; Staffieri A
    J Infect; 2006 Nov; 53(5):e219-22. PubMed ID: 16545459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
    Li C; Kuti JL; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathologic features of Burkholderia cepacia pneumonia in patients without cystic fibrosis.
    Belchis DA; Simpson E; Colby T
    Mod Pathol; 2000 Apr; 13(4):369-72. PubMed ID: 10786801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of meropenem.
    Nicolau DP
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S32-40. PubMed ID: 18713048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temocillin in cystic fibrosis: a retrospective pilot study.
    Kent L; Bradley JM; France M; Döring G; Carryn S; Bradbury I; Rendall J; Jones A; Elborn JS
    J Cyst Fibros; 2008 Nov; 7(6):551-4. PubMed ID: 18706868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.